Skip to Main Content

WASHINGTON — Whether seniors get an unprecedented mid-year discount on Medicare premiums will hinge on a forthcoming decision about how the program will cover a pricey, controversial new Alzheimer’s drug that is expected by mid-April.

Health and Human Services Secretary Xavier Becerra said two months ago he wanted to explore lowering the premiums, which saw their largest-ever hike this year in case Medicare spending skyrocketed due to the approval of Aduhelm, which initially cost more than $56,000 for one patient, for one year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment